study to assess the safety, tolerability, and pharmacokinetics (movement of drugs within the body) of azd2693 in healthy participants

Conditions: Healthy Participants

Summary: this phase i, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (pk) of azd2693 following subcutaneous (sc) administration of azd2693 in healthy participants

the study will be performed at a single study center in japan. the study will comprise of following periods: * screening period of maximum 28 days. * an 8-week treatment period during which participants will be randomized to receive multiple doses of azd2693 or placebo at the study center. * a follow-up period of 15 weeks post last dose of study intervention consisting of 8 follow-up visits. participants will be enrolled in 4 consecutive cohorts of 11 participants where 8 participants will be randomized to receive azd2693 and 3 participants will be randomized to receive placebo. a participant is considered to have completed the study if the participant has completed all phases of the study including the last visit.

Eligibility criteria:
inclusion criteria: * participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * participants who are of japanese ethnicity (japanese participant is defined as having both parents and 4 grandparents who are ethnically japanese and this also includes second and third generation japanese whose parents or grandparents are living in a country other than japan) * participants who are of non-asian ethnicities. a non-asian participant is defined as having both parents and grandparents who are ethnically non-asian. * body mass index within the range 18 to 32 kg/m\^2 * male and/or female participants of non-child bearing potential exclusion criteria: * history of any clinically important disease or disorder * history or presence of gastrointestinal, hepatic, or renal disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs * participants with known autoimmune disease or on-treatment with immune-modulatory drugs * any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first dose of study intervention * any clinically significant cardiovascular event within the last 6 months prior to the screening visit * any clinically important abnormalities in clinical chemistry, haematology or urinalysis results and any abnormal vital signs * any clinically important abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ecg) and any clinically important abnormalities in the 12-lead ecg * blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding * history of major bleed or high-risk of bleeding diathesis * participants with a positive diagnostic nucleic acid test for severe acute respiratory syndrome coronavirus 2 (sars-cov-2), at screening visit. participants who test positive for coronavirus disease 2019 (covid-19) at screening visit * participants with a significant covid-19 illness within 6 months of enrollment * history of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity * received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days of last follow-up to first dose of study intervention of this study or 5 half-lives from last dose to first dose of study intervention, whichever is the longest * participants who have previously received azd2693 * previous enrollment or randomization into the present study

Keywords: pharmacokinetics healthy japanese participants non-alcoholic fatty liver disease non-alcoholic steatohepatitis